Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.4B
15M shares
52-week range
$13.97 – $155.29
58% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $9.1M | $12.8M | $7.1M | $2.2M | $1.8M | $200.0K | $1.3M |
| Cost of revenue | $33.5M | $47.9M | $73.5M | $2.7M | $110.2M | $1.2M | $2.3M | $2.5M |
| Gross profit | −$26.0M | −$38.8M | −$60.7M | $4.4M | −$108.0M | $609.0K | −$2.1M | −$1.2M |
| Gross margin | -346.1% | -426.9% | -473.8% | 62.3% | -4926.7% | 33.8% | -1042.5% | -91.0% |
| R&D | $33.5M | $47.9M | $73.5M | $71.4M | $110.2M | $190.6M | $203.7M | $113.0M |
| Operating income | −$29.5M | −$43.7M | −$67.4M | −$76.6M | −$129.1M | −$219.2M | −$331.4M | −$135.0M |
| EBITDA | −$28.8M | −$42.6M | −$63.8M | −$75.4M | −$125.8M | −$206.7M | $1.70B | −$132.5M |
| Net income | −$31.2M | −$51.4M | −$75.6M | −$81.8M | −$145.2M | −$241.4M | $1.69B | −$140.1M |
| Net margin | -415.5% | -565.3% | -590.5% | -1147.6% | -6625.3% | -13408.9% | 843786.0% | -10773.5% |
| EPS (diluted) | -1.15 | -1.41 | -2.99 | -2.15 | -3.62 | -5.12 | 116.58 | -9.04 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-9.23 | $-11.84–$-6.63 | 1 |
| 2027 | $57M | $-6.53 | $-8.37–$-4.69 | 1 |
| 2028 | $131M | $-3.98 | $-5.10–$-2.85 | 1 |
| 2029 | $203M | $-2.73 | $-3.50–$-1.96 | 1 |
Forward consensus · source: Financial Modeling Prep
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
www.inhibrx.comNo one on the platform currently holds INBX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 50,183 | $3.4M |
No one on the platform has traded INBX yet.
| $3.6B |
| — |
| IMTXImmatics N.V. | $9.56 | +0.42% | $1.3B | — |
| NKTRNektar Therapeutics | $65.39 | +2.73% | $1.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 7070.3× sales vs its 401.0× historical median P/S.
Fair value ≈ $5.42 · price $95.50 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$INBX keep hearing about buyouts but stock is not moving.
View on StockTwits ↗$APGE news is out that $ABBV is buying APGE for a big premium. APGE was one of 3 buyout targets (other 2 were $COGT & $INBX) mentioned by the biotech analyst on CNBC Fast Money last night..
View on StockTwits ↗$INBX the first company to show efficacy via OX40 agonism in a randomized setting. Severely undervalued.
View on StockTwits ↗$GDC Could be the next big run $DGXX $MTEN $INBX
View on StockTwits ↗$INBX Great news yesterday but no real stock movement - If only Inhibrx was a Rocket/Internet Provider/AI company it would be able to loss a ton of money - have no real visability on when it could become profitiable and piss away money and yet have a over 2T market cap and keep going up. - Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
View on StockTwits ↗$INBX What the Funk is going on here??? I closed out at $133 and YOU people let it get this low??? OK ..... Just bought 250 shares. Now, lets get it where it belongs ..... $200+++
View on StockTwits ↗$INBX Starter. I'm not saying buy zone, but pretty close....Now if the market corrects that 20% everyone is expecting, then yea $68
View on StockTwits ↗$INBX $ATER $KODK $PZZA I call the kinds of stocks I uncover and invest in, like $SLS and all the others I listed in the re-post below-- Special Situation Stocks ... They could just as easily be called "wake up stocks", because there is nothing to do but HOLD ON TO THEM until you wake up one morning to great headline news and a massive upward re-pricing adjustment !!! ... FOLLOW me 👉 @Mike22332233 for all my latest Special Situation Stocks for FAST & LARGE GAINS
View on StockTwits ↗MY TOP SPECIAL SITUATION STOCK HOLDINGS & EXPECTED % RETURNS ... 1) SLS 1,650%-2,650% 2) $INBX 300%-500% 3) $ATER 100%-300% 4) $KODK 50%-100% 5) $PZZA 57%-63% 6) ZIM 43%-51% 7) WEN 40%-46% 8) MNRO 41%-45% 9) DDI 35%-52% 10) LSTA 50% 11) PRTH 21%
View on StockTwits ↗@Mike22332233 Mike DM me would love to discuss $INBX
View on StockTwits ↗$INBX $SLS I would concur that it has one of the best potential for an asymmetrical return I’ve ever seen. The length the Regal clinical trial has gone on is astonishing. AML is such a rapid, ruthless and brutal killer especially if you can’t get a stem cell transplant. The fact that this trial has gone on for six years and more than two years after the last patient was enrolled is astonishing if you know anything about AML leukemia, which unfortunately I do. No, there are no guarantees in the market, but this is about the best setup in a clinical trial I’ve ever seen.  I normally don’t size up my bio investments quite this much.
View on StockTwits ↗$SLS $SLS is my #1 largest holding in a $1.4 mil portfolio, with the best asymmetrical return potential I have ever seen in my 43 years of investing… ALL profits from my Special Situation Stocks go into more SLS ... My #2 holding is $INBX ... They have 2 major assets/platforms: Ozekibart (INBX-109) which may be worth $3-$4 Bil, and INBX-106 which may be worth $5-$6 Bil ... with some people putting a much higher value on each … Here is the play on $INBX ... They will sell one of these 2 for BILLIONS and then spin off the other one (and the rest of pipeline) into a new Company .... They have done this EXACT thing in the past !!! ... Considering that INBX at $90.46 today has a market cap of $1.33 BIL, you can see how RIDICULOUSLY undervalued it is if I am correct in my analysis!!!! .... I expect sale to occur in next 1-3 months and then followed quickly with the spinoff !!! ... LIKE if you agree ... FOLLOW me @Mike22332233 for all the newest updates on my Special Situation Stocks
View on StockTwits ↗Targeted therapy shows promise for patients with advanced colorectal cancer in a first-in-human study $inbx 👀 https://www.icr.ac.uk/about-us/icr-news/detail/targeted-therapy-shows-promise-for-patients-with-advanced-colorectal-cancer-in-a-first-in-human-study
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.